ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements
Mangalam Drugs and Organics Limited announced the appointment of new Statutory and Secretarial Auditors following the tenure completion of the previous Statutory Auditor.
Manglam Drugs and Organics Ltd. has appointed M/s S.N. Nanda & Co. as Statutory Auditor and M/s L.N. Joshi & Co. as Secretarial Auditor.
Mangalam Drugs and Organics Ltd held its 53rd Annual General Meeting on September 23, 2026. The meeting transacted standard business items including financial statement adoption and auditor appointments.
Mangalam Drugs and Organics reported a bank default amounting to Rs. 15.57 Crore. The company has submitted a restructuring proposal to the banks for resolution.
Mangalam Drugs disclosed a default on loan obligations to Bank of Maharashtra and Bank of Baroda, totaling ₹15.57 Crore in overdue amounts.
Mangalam Drugs and Organics Limited has appointed Mr. Prabhakar Raghunath Zavar as a Non-Executive Independent Director, effective September 15, 2026.
Mangalam Drugs & Organics appointed Mr. Prabhakar Raghunath Zavar as an Additional Independent Non-Executive Director for a five-year term at the latest board meeting.
Mangalam Drugs and Organics Limited scheduled its 53rd Annual General Meeting for September 23, 2026. The meeting will be held via video conferencing.
Mangalam Drugs disclosed defaults on loan obligations to Bank of Baroda and Bank of Maharashtra, totaling ₹15.57 Crore in overdue amounts.
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹57.1 Cr (-0.2% YoY) and a net loss of ₹7.6 Cr for Q1 FY27.
Mangalam Drugs and Organics Limited announced the cessation of its Secretarial Auditor, M/s. Ragini Chokshi & Co., due to resignation effective August 4, 2026.
Mangalam Drugs and Organics Limited informed the exchanges that M/s. Ragini Chokshi & Co. has resigned as the company's Secretarial Auditor effective August 4, 2026.
Mangalam Drugs & Organics will hold a board meeting on August 12, 2026, to consider unaudited financial results and appoint auditors.
Mangalam Drugs and Organics reported a Rs. 15.57 Crore default on cash credit facilities. The defaults involve Bank of Baroda and Bank of Maharashtra accounts.
Mangalam Drugs reported a Rs.15.57 Crore bank default. The company has submitted a restructuring proposal to lenders to address the liability.
Mangalam Drugs and Organics reported a Rs 15.57 Crore default on cash credit facilities from two banks. The company is arranging funds to clear the overdue amounts.
Mangalam Worldwide submitted a security cover certificate for Rs. 50.19 Crore NCDs. The market value security cover ratio is 1.27.
Mangalam Worldwide Limited filed a Title Search Report confirming clear and marketable title for its industrial land in Sanand, Ahmedabad. This routine legal disclosure verifies ownership.
Mangalam Drugs and Organics filed its Annual Secretarial Compliance Report for FY2026. The report notes certain governance non-compliances regarding board and committee compositions.
Mangalam Drugs and Organics seeks shareholder approval via postal ballot for Shri Praveen Saxena's re-appointment. E-voting commences May 19, 2026, for a second five-year term.
Mangalam Drugs and Organics reported a ₹15.58 Crore bank default. The company has submitted a restructuring proposal to lenders to address the situation.
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹67.3 Cr (-7.6% YoY) and a net loss of ₹13.4 Cr for Q4 FY26.
Mangalam Drugs & Organics Ltd reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The Board approved the audited performance today.
Mangalam Drugs and Organics Limited has scheduled a board meeting for May 14, 2026, to consider and approve its audited standalone and consolidated financial results for the year ended March 31, 2026. The company's trading window remains closed until May 16, 2026, in compliance with insider trading regulations.
Mangalam Drugs and Organics Limited has scheduled a board meeting on May 14, 2026, to consider and approve audited financial results for the quarter and year ended March 31, 2026. Consequently, the trading window for dealing in company securities is closed from April 1, 2026, until 48 hours after the results announcement.
Shree Kishoriju Trading and Investments Private Limited, a promoter group entity of Mangalam Drugs & Organics Limited, announced the release of 1,500 pledged equity shares. The release occurred on February 6, 2026, reducing the encumbered portion of their 3.21% stake. This move indicates a marginal reduction in the promoter group's pledged shareholding.
Shree Rasbihari Trading and Investments Private Limited, a promoter group entity of Mangalam Drugs & Organics Limited, has released 1,73,000 pledged shares (1.09% stake). This release of encumbrance reduces the total pledged holdings of the promoter group, potentially improving the company's risk profile for investors.
Promoter Aditya Ramniwas Dhoot released 89,000 pledged shares (0.56% stake) of Mangalam Drugs & Organics Limited on March 16, 2026. The shares were previously encumbered in favor of M/s Famy care Private Ltd as security for debt. Following this release, the promoter's pledged holding in the company has been reduced to zero.
Shree Kishoriju Trading and Investments Private Limited, a promoter group entity of Mangalam Drugs and Organics Limited, announced the release of 1,500 pledged shares on June 2, 2026. This release reduces the promoter's encumbered shareholding from 0.00% to nil, bringing their total post-event holding to 5,08,599 shares.
Mangalam Drugs and Organics Limited announced the resignation of Ms. Anuradha Pandey as Company Secretary and Compliance Officer, effective March 29, 2026. She resigned to pursue opportunities outside the company. The filing includes an explanation for a slight delay in disclosure due to administrative oversight.